In 1994, the FDA approved [111In]In-pentetreotide (OctreoScanTM) as the first somatostatin receptor subtype 2 (SSTR2) targeting radiotracer for SPECT imaging of SSTR2-positive neuroendocrine tumours (NETs) [9]. The gene discussed is SSTR2; the disease is neuroendocrine neoplasm.